Press Release Distribution

Members Login  |  Register  |  Why Join?   Follow us on Google+Follow us on TwitterFind us on LinkedInFind Us on FacebookSubscribe to our RSS FeedsSubscribe to our YouTube ChannelFind us on RebelMouse

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Date    |    Business Directory
All Press Releases for January 15, 2014 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version   

Dr. Michael Har-Noy Describes His New Phase I/II trial of CRCL-AlloVaxTM

Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., a biotechnology company in Israel, describes his new Phase I/II trial of CRCL-AlloVaxTM, a new cancer vaccine.
x-small text small text medium text large text

    DENVER, CO, January 15, 2014 /24-7PressRelease/ -- Dr. Michael Har-Noy and his company, Immunovative Therapies, Ltd., will be conducting a Phase I/II clinical trial of CRCL-AlloVaxTM, a new cancer vaccine. Dr. Michael Har-Noy indicates that this new compound has potential activity against a wide variety of tumors. The drug will be administered in Thailand as part of a "Compassionate Use Program" or "CUP", also called an "Expanded Access Program". The study will provide metastatic cancer patients with an experimental treatment option after that have stopped responding to chemotherapy.

This study is not designed to be an alternative to conventional cancer treatment. Dr. Michael Har-Noy states that he intends to test the experimental anti-cancer vaccine in patients that have tried and failed available conventional therapies, such as chemotherapy and radiation.

Dr. Michael Har-Noy goes on to say that the study will test the positive and negative effects of the experimental therapeutic cancer vaccine CRCL-AlloVax in a variety of different tumor cell types. The vaccine is engineered to train the patient's immune system to identify and kill malignant cells that were previously ignored by the host immune response. Dr. Michael Har-Noy hopes that the vaccine will provide a minimally toxic treatment for metastatic cancer patients resulting in decreased tumor bulk and/or slower tumor growth. Dr. Michael Har-Noy adds that this tumor reduction may lead to a better quality of life and increased patient survival. However, at this time it is not known how well patients will respond, or if they will respond at all to CRCL-AlloVax.

Data from this clinical trial is intended to provide medical scientists with preliminary data. Researchers may then use these study results to determine which types of malignancies respond best to this vaccine. Dr. Michael Har-Noy goes on to add that this study data may indicate whether any response to the vaccine correlates with other predictive factors, such as amount of tumor, age, tumor location, amounts and types of prior cancer therapy, and immune status at the time of treatment.

Dr. Michael Har-Noy states that while this experimental anti-cancer vaccine may result in increased longevity for many types of cancer patients, there is currently insufficient data to make any claims about its ultimate efficacy. It is possible that some patients will have a good response and others have none. Dr. Michael Har-Noy adds that it is also possible that the vaccine will demonstrate no benefit or may even have a tumor enhancing effect. Preliminary data, however, indicates that this would be unlikely.

Dr. Michael Har-Noy says that most approved and currently marketed cancer drugs do not work for all patients and usually have very significant side-effects. Although not all patients benefit from any given approved therapy, the likelihood that a person will respond is known and can be considered by the patient before he decides to try the drug. However, in the case of an experimental drug, such as CRCL-AlloVaxTM, no information is available to predict how a study patient will respond.

In a previously conducted Phase I/II trial of AlloStimTM, the parent compound of CRCL-AlloVaxTM, forty-two study patients with a wide variety of tumors that were given AlloStimTM had almost three times the predicted survival of historic controls. Dr Michael Har-Noy says that these remarkable results will soon be published in a peer-reviewed journal.

About: Dr. Michael Har-Noy is the founder and CEO of Immunovative Therapies, Ltd. an Israeli biotechnology company. Dr. Michael Har-Noy is developing and testing revolutionary immune-based cancer treatments that, when marketed, will likely revolutionize the field of oncology.

Press release service and press release distribution provided by

# # #

Read more Press Releases from Bethany Franklin:

Contact Information:
Bethany Franklin

Denver, CO
Voice: 1-800-701-6787
E-Mail: Email us Here
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7PressRelease. We are unable to assist you with any information regarding this release. 24-7PressRelease disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.